Evidence map›Paper›PMID 39403573›Full record

ArticleClinical and translational radiation oncology2024

Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.

Patrick Carriere, Omar Alhalabi, Jianjun Gao, Osama Mohamad, Matthew T Campbell, Amishi Shah, Sangeeta Goswami, Kelly Bree, Byron Lee, Neema Navai and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Patrick CarriereDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Omar AlhalabiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Osama MohamadDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew T CampbellDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amishi ShahDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sangeeta GoswamiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly BreeDepartment of Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Byron LeeDepartment of Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neema NavaiDepartment of Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Henry MokDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren MayoDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Charles GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Quynh NguyenDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sean McGuireDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ryan ParkDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shalin ShahDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karen HoffmanDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steven FrankDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chad TangDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seungtaek ChoiDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashish KamatDepartment of Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Comron HassanzadehDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Trimodality therapy for muscle-invasive bladder cancer (MIBC) yields similar oncologic outcomes compared to radical cystectomy in appropriately selected patients; however, data regarding locally advanced MIBC (LA-MIBC) is limited. We explored our experience with LA-MIBC undergoing radiation therapy (RT). Methods: We retrospectively identified 30 patients from an institutional prospectively collated database with non-metastatic, LA-MIBC. Patients with T3-4 N0 or T2-4 N + treated from 2012 to 2022 with definitive-intent RT, who were not candidates for cystectomy were included. Kaplan-Meier analysis was used to estimate time-to-event outcomes, and multivariate analyses were conducted using Cox proportional hazards modeling. Results: 43 % had T3N0 disease, 30 % had T4N0 disease, and 27 % had node positive disease.. Neoadjuvant chemotherapy/systemic therapy was administered in 63 % of patients. Median dose and fractionation of RT was 60 Gy in 30 fractions. 23 % of patients received hypofractionated RT, 57 % received nodal RT.At a median follow-up of 20 (range, 1-75) months after RT, estimated 1- and 2-year OS was 73 % and 61 %, respectively. Estimated 1-year progression-free survival was 50 %. Local bladder failure was a component of progression in 17 % of patients, and all local bladder failure events occurred within the first 12 months following RT. Lymph node or distant metastases occurred in 23 % of patients. Estimated 1-year OS was 83 % with pure urothelial histology but only 58 % with variant histology (P = 0.001). Late grade 3 + GU and GI toxicity occurred in 7 % and 5 % of patients, respectively. Conclusions: In this cohort with LA-MIBC treated with RT, distant failures predominate, local failures are less common, and toxicity was minimal. Survival outcomes remain encouraging for RT in this challenging patient population. Further investigation is warranted to identify biomarkers for patient selection and strategies to improve distant control.

Identifiers

PMID39403573
PMCPMC11472623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.